The diagnosis of GBM is now exclusive for IDH wild-type tumors with specific molecular features (gains in chromosome 7 and losses in chromosome 10, EGFR amplifications, and TERT promoter mutations), independent of the histopathological grade [11,26]. This evidence concerns the gene TERT and glioblastoma.